NEW YORK (360Dx) – Nightingale Health announced on Monday that its blood analysis biomarker system has received CE marking for the measurement of creatinine and glucose.

The Finnish company's system is based on nuclear magnetic resonance spectroscopy, and is designed to capture and analyze over 228 metabolic biomarkers from a single blood sample. The technology has previously been available for research use only to assess a patient's risk for developing diabetes and cardiovascular disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.